Table 1.
Characteristics of cancer patients receiving ustekinumab for ircAEs.
| All Patients (n = 14) | Responders to Ustekinumab (n = 10) | Non-Responders to Ustekinumab (n = 4) | p-Value | ||
|---|---|---|---|---|---|
| Age | Median (IQR) | 71 (10) | 71 (24) | 72 (12) | 0.515 |
| Sex, n (%) | Female | 6 (42.9) | 3 (75) | 3 (30) | 0.125 |
| Male | 8 (57.1) | 1 (25) | 7 (70) | ||
| Race, n (%) | White | 14 (100) | 4 (100) | 10 (100) | -- |
| Non-Hispanic | 14 (100) | 4 (100) | 10 (100) | -- | |
| Cancer type, n (%) | Breast cancer | 1 (7.1) | 1 (25) | 0 (0) | 0.708 |
| Lymphoma | 1 (7.1) | 0 (0) | 1 (10) | ||
| Melanoma | 4 (28.6) | 1 (25) | 3 (30) | ||
| Pancreatic | 1 (7.1) | 0 (0) | 1 (10) | ||
| Genitourinary | 7 (14.3) | 1 (25) | 1 (10) | ||
| ICB type, n (%) | Atezolizumab | 1 (7.1) | 0 (0) | 1 (10) | 0.375 |
| Avelumab | 1 (7.1) | 0 (0) | 1 (10) | ||
| Nivolumab | 3 (21.4) | 2 (50) | 1 (10) | ||
| Pembrolizumab | 9 (64.3) | 2 (50) | 7 (70) |